Darolutamide Clinical Trials
25 recruitingDrug
Phase 213Phase 110Phase 35
Showing 1–20 of 25 trials
Recruiting
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
Prostatic Neoplasms
Bayer1,400 enrolled1 locationNCT07406282
Recruiting
Phase 1Phase 2
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals155 enrolled22 locationsNCT07190300
Recruiting
Phase 3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca1,800 enrolled410 locationsNCT06120491
Recruiting
Phase 2
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
Swiss Cancer Institute162 enrolled13 locationsNCT06401980
Recruiting
Phase 1
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC300 enrolled15 locationsNCT05818683
Recruiting
Phase 2
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Prostate CancerHigh-risk Prostate Cancer
Icahn School of Medicine at Mount Sinai40 enrolled1 locationNCT07027124
Recruiting
Phase 2Phase 3
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
Prostate Cancer
Cancer Research Antwerp493 enrolled9 locationsNCT06282588
Recruiting
Phase 2
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Stage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Advanced Prostate Adenocarcinoma
University of California, Davis75 enrolled1 locationNCT06173362
Recruiting
Phase 2
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins60 enrolled1 locationNCT07142551
Recruiting
Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Hormone-refractory Prostate Cancer
Vir Biotechnology, Inc.390 enrolled9 locationsNCT05997615
Recruiting
Phase 1
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
Prostate Cancer
AstraZeneca120 enrolled19 locationsNCT05938270
Recruiting
Phase 1
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Amgen60 enrolled11 locationsNCT07140900
Recruiting
Phase 1
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
Prostate Cancer SurgeryProstate Cancer (Adenocarcinoma)Prostate CA
AdventHealth30 enrolled1 locationNCT06631521
Recruiting
Phase 1
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo60 enrolled6 locationsNCT07244341
Recruiting
Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Prostate CancerMetastatic Castration-resistant Prostate Cancer
Janux Therapeutics272 enrolled35 locationsNCT05519449
Recruiting
Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Prostate Adenocarcinoma
NRG Oncology2,050 enrolled575 locationsNCT05050084
Recruiting
Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Biochemically Recurrent Prostate CarcinomaRecurrent Castration-Sensitive Prostate CarcinomaRecurrent Prostate Cancer+1 more
Mayo Clinic532 enrolled3 locationsNCT06378866
Recruiting
Phase 2
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Triple-Negative Breast Carcinoma
Vandana Abramson51 enrolled1 locationNCT07016399
Recruiting
Phase 3
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Prostate CancerHigh Risk Prostate Carcinoma
UNICANCER700 enrolled6 locationsNCT06625970
Recruiting
Phase 2
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
Metastatic Prostate Cancer
St Vincent's Hospital, Sydney22 enrolled2 locationsNCT04925648